UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$25.3B |
| 2 |
Bank of America
BAC
|
+$1.96B |
| 3 |
Applied Materials
AMAT
|
+$1.43B |
| 4 |
NetEase
NTES
|
+$1.18B |
| 5 |
Union Pacific
UNP
|
+$870M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$7.17B |
| 2 |
Apple
AAPL
|
+$3.39B |
| 3 |
UBS Group
UBS
|
+$2.73B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$2.53B |
| 5 |
Meta Platforms (Facebook)
META
|
+$2.04B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.88% |
| 2 | Financials | 12.37% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Healthcare | 9.66% |
| 5 | Communication Services | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
601
Commault Systems
CVLT
$6.18B
| $50.6M | 0.01% |
268,192
-14,679
| -5% | -$2.65M |
2013 Q2
49 quarters
|
|
602
Nordson
NDSN
$18B
| $50.4M | 0.01% |
222,193
-43,595
| -16% | -$9.6M |
2013 Q2
49 quarters
|
|
603
MP Materials
MP
$7.15B
| $49.6M | 0.01% |
740,062
-396,624
| -35% | -$25M |
2023 Q1
10 quarters
|
|
604
Kymera Therapeutics
KYMR
$8.71B
| $48.9M | 0.01% |
863,762
+44,835
| +5% | +$2.02M |
2021 Q2
17 quarters
|
|
605
British American Tobacco
BTI
$129B
| $47.9M | 0.01% |
+901,511
| New | +$48.9M |
2025 Q3
0 quarters
|
|
606
Unum
UNM
$14.6B
| $47.7M | 0.01% |
613,691
-325,478
| -35% | -$24.4M |
2013 Q2
49 quarters
|
|
607
Reinsurance Group of America
RGA
$17.4B
| $47.6M | 0.01% |
247,806
-131,952
| -35% | -$25.3M |
2013 Q2
49 quarters
|
|
608
Casey's General Stores
CASY
$25.5B
| $47.5M | 0.01% |
83,974
-46,221
| -36% | -$24.2M |
2013 Q2
49 quarters
|
|
609
Amdocs
DOX
$6.27B
| $47M | 0.01% |
572,444
-10,931
| -2% | -$948K |
2013 Q2
49 quarters
|
|
610
A.O. Smith
AOS
$8.05B
| $46.8M | 0.01% |
637,389
-137,677
| -18% | -$9.8M |
2013 Q2
49 quarters
|
|
611
TechnipFMC
FTI
$27.3B
| $46.8M | 0.01% |
1,185,459
-552,718
| -32% | -$20.2M |
2017 Q3
32 quarters
|
|
612
ReNew
RNW
$2.51B
| $46.5M | 0.01% |
6,034,739
-48,309
| -0.8% | -$368K |
2025 Q1
2 quarters
|
|
613
East-West Bancorp
EWBC
$17.4B
| $46.4M | 0.01% |
436,020
-214,901
| -33% | -$22.6M |
2013 Q2
49 quarters
|
|
614
Tenet Healthcare
THC
$21.5B
| $46.4M | 0.01% |
228,492
-134,141
| -37% | -$23.8M |
2013 Q2
49 quarters
|
|
615
CareTrust REIT
CTRE
$8.64B
| $45.4M | 0.01% |
1,308,559
-292,678
| -18% | -$9.6M |
2014 Q2
45 quarters
|
|
616
DELISTED
Janus Henderson
JHG
| $45.1M | 0.01% |
1,013,534
-216,374
| -18% | -$9.34M |
2017 Q2
33 quarters
|
|
617
Globe Life
GL
$13B
| $44.5M | 0.01% |
311,264
-123,410
| -28% | -$16.7M |
2013 Q2
49 quarters
|
|
618
Huazhu Hotels Group
HTHT
$14.7B
| $44.5M | 0.01% |
1,137,700
+889,869
| +359% | +$31.1M |
2017 Q4
31 quarters
|
|
619
Levi Strauss
LEVI
$7.84B
| $44.5M | 0.01% |
1,908,682
+160,855
| +9% | +$3.42M |
2023 Q1
10 quarters
|
|
620
RenaissanceRe
RNR
$14.6B
| $44.4M | 0.01% |
175,041
-47,289
| -21% | -$11.5M |
2013 Q2
49 quarters
|
|
621
DaVita
DVA
$12B
| $44.4M | 0.01% |
334,365
-91,788
| -22% | -$12.6M |
2013 Q2
49 quarters
|
|
622
AXIS Capital
AXS
$7.27B
| $44.4M | 0.01% |
463,071
-143,014
| -24% | -$13.8M |
2013 Q2
49 quarters
|
|
623
Royal Gold
RGLD
$20.2B
| $44.3M | 0.01% |
220,924
-117,054
| -35% | -$20.2M |
2013 Q2
49 quarters
|
|
624
Littelfuse
LFUS
$9.7B
| $44.3M | 0.01% |
170,971
-47,119
| -22% | -$11.8M |
2013 Q2
49 quarters
|
|
625
Rhythm Pharmaceuticals
RYTM
$5.93B
| $44.2M | 0.01% |
437,472
+209,845
| +92% | +$19.5M |
2020 Q2
21 quarters
|
|
Similar funds
UBS AM's Q3 2025 Portfolio in Review
As of Q3 2025, UBS AM held 2,672 positions worth $461B, down 6.8% from $494B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
UBS AM withdrew a net $68.7B in Q3 2025, closing 403 positions and reducing 2,008 holdings. Its most notable exit was Pinduoduo, an estimated $967M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, UBS AM opened a new position in Vanguard Dividend Appreciation ETF worth $135M.
- UBS AM's largest Q3 2025 buy was Vanguard Dividend Appreciation ETF: 624,303 shares worth $135M.
- UBS AM added most to Microsoft in Q3 2025, an estimated $25.3B increase.
- UBS AM's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $7.17B.
- UBS AM fully exited Pinduoduo in Q3 2025, selling an estimated $967M.
- UBS AM's ten largest holdings make up 35% of its $461B portfolio in Q3 2025.
- UBS AM opened 67 new positions and closed 403 in Q3 2025.
- UBS AM's portfolio value fell 6.8% quarter-over-quarter to $461B.
Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.